紫杉醇和帕博利珠单抗在铂类难治性上皮性卵巢癌伴广泛血栓栓塞病例中的超说明书用药
Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism.
作者信息
Lam Clarissa, Ha Kristal, Hakam Ardeshir, Shahzad Mian M K
机构信息
Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, USA.
Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
出版信息
Gynecol Oncol Rep. 2022 May 2;41:100992. doi: 10.1016/j.gore.2022.100992. eCollection 2022 Jun.
Abstract
•Management of platinum refractory ovarian cancer is challenging.•Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy.•Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option.
摘要
•铂耐药卵巢癌的管理具有挑战性。
•广泛的静脉血栓栓塞排除了抗血管生成联合化疗。
•每周紫杉醇与免疫检查点抑制剂联合提供了一种持久的肿瘤控制选择。
Zotero 插件